Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.20
NAS:ARLZ's Cash-to-Debt is ranked lower than
79% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.05 vs. NAS:ARLZ: 0.20 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ARLZ' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.2  Med: No Debt Max: No Debt
Current: 0.2
Equity-to-Asset 0.15
NAS:ARLZ's Equity-to-Asset is ranked lower than
94% of the 731 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. NAS:ARLZ: 0.15 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ARLZ' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.15  Med: 0.66 Max: 0.97
Current: 0.15
0.15
0.97
Debt-to-Equity 3.66
NAS:ARLZ's Debt-to-Equity is ranked lower than
96% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.30 vs. NAS:ARLZ: 3.66 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:ARLZ' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.43  Med: 1.4 Max: 3.66
Current: 3.66
0.43
3.66
Piotroski F-Score: 3
Altman Z-Score: -1.09
Beneish M-Score: -2.31
WACC vs ROIC
4.56%
-36.13%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -101.97
NAS:ARLZ's Operating Margin % is ranked lower than
87% of the 758 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.95 vs. NAS:ARLZ: -101.97 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ARLZ' s Operating Margin % Range Over the Past 10 Years
Min: -477.51  Med: -18.61 Max: 51.17
Current: -101.97
-477.51
51.17
Net Margin % -122.35
NAS:ARLZ's Net Margin % is ranked lower than
88% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.06 vs. NAS:ARLZ: -122.35 )
Ranked among companies with meaningful Net Margin % only.
NAS:ARLZ' s Net Margin % Range Over the Past 10 Years
Min: -472.67  Med: -15.18 Max: 60.74
Current: -122.35
-472.67
60.74
ROE % -87.33
NAS:ARLZ's ROE % is ranked lower than
90% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.91 vs. NAS:ARLZ: -87.33 )
Ranked among companies with meaningful ROE % only.
NAS:ARLZ' s ROE % Range Over the Past 10 Years
Min: -153.39  Med: -18.31 Max: 60.98
Current: -87.33
-153.39
60.98
ROA % -25.74
NAS:ARLZ's ROA % is ranked lower than
84% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. NAS:ARLZ: -25.74 )
Ranked among companies with meaningful ROA % only.
NAS:ARLZ' s ROA % Range Over the Past 10 Years
Min: -91.36  Med: -9.78 Max: 45.87
Current: -25.74
-91.36
45.87
ROC (Joel Greenblatt) % -1544.97
NAS:ARLZ's ROC (Joel Greenblatt) % is ranked lower than
93% of the 793 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.48 vs. NAS:ARLZ: -1544.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ARLZ' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -30241.44  Med: -1967.27 Max: 48760.69
Current: -1544.97
-30241.44
48760.69
3-Year Revenue Growth Rate 37.30
NAS:ARLZ's 3-Year Revenue Growth Rate is ranked higher than
94% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. NAS:ARLZ: 37.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ARLZ' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 8.9 Max: 54.5
Current: 37.3
0
54.5
3-Year EBITDA Growth Rate 35.10
NAS:ARLZ's 3-Year EBITDA Growth Rate is ranked higher than
85% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. NAS:ARLZ: 35.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ARLZ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -37  Med: -5.6 Max: 119.8
Current: 35.1
-37
119.8
3-Year EPS without NRI Growth Rate 46.80
NAS:ARLZ's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.60 vs. NAS:ARLZ: 46.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ARLZ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -52.8  Med: -8.15 Max: 71.8
Current: 46.8
-52.8
71.8
GuruFocus has detected 5 Warning Signs with Aralez Pharmaceuticals Inc $NAS:ARLZ.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ARLZ's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

ARLZ Guru Trades in

Q1 2016

ARLZ Guru Trades in Q1 2016

Jim Simons 610,819 sh (New)
Paul Tudor Jones 19,500 sh (New)
Steven Cohen 636,652 sh (New)
Charles Brandes 30,474 sh (unchged)
» More
Q2 2016

ARLZ Guru Trades in Q2 2016

Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Jim Simons 538,301 sh (-11.87%)
Charles Brandes 15,473 sh (-49.23%)
» More
Q3 2016

ARLZ Guru Trades in Q3 2016

Jim Simons Sold Out
Charles Brandes Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:ARLZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Charles Brandes 2016-09-30 Sold Out $3.46 - $6.26 $ 1.42-69%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 3741
Compare:TSXV:THCX, TSX:CPH, TSXV:RX, TSXV:HIP, XCNQ:BCC, XCNQ:MDM, TSXV:MGW, TSX:NRI, XCNQ:IN, TSXV:WMD, XCNQ:ISOL, XCNQ:MJ, XCNQ:GLH, XCNQ:EAT, TSX:ASP, XCNQ:TER, XCNQ:TGIF, XCNQ:HC, XCNQ:PUF, OTCPK:SBFM » details
Traded in other countries:ARZ.Canada, AZL.Germany,
Headquarter Location:Canada
Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in delivering products to improve patients' lives by acquiring, developing and commercializing products in cardiovascular, pain and other specialty areas.

POZEN Inc was incorporated in the State of Delaware on September 25, 1996. The Company is a pharmaceutical company focused on transforming medicines that can transform lives. The Company is engaged in developing products that address unmet medical needs in the marketplace, obtaining patents for those ideas which the company believes has value in the marketplace, utilizing a small group of talented employees to develop those ideas by working with strategic outsource partners, developing a regulatory pathway with the appropriate agency, and determining how to commercialize its products. The Ccompany has developed Treximet in collaboration with GlaxoSmithKline, or GSK. Treximet is the brand name for the product combining sumatriptan 85 mg, formulated with RT Technology and naproxen sodium 500 mg in a single tablet designed for the acute treatment of migraine. The Company has also developed VIMOVO with AstraZeneca AB, or AstraZeneca. VIMOVO (formerly referred to as PN 400) is the brand name for a proprietary fixed dose combination of the PPI esomeprazole magnesium with the NSAID naproxen in a single tablet. The competition for VIMOVO comes from the oral anti-arthritic market, or more specifically the traditional non-selective NSAIDs (such as naproxen and diclofenac), traditional NSAID/gastroprotective agent combination products or combination product packages (such as Arthrotec and Prevacid NapraPAC) and the only remaining COX-2 inhibitor, Celebrex. The Companys product candidates under development are subject to extensive domestic and foreign regulation.

Ratios

vs
industry
vs
history
PB Ratio 1.29
ARLZ's PB Ratio is ranked higher than
90% of the 751 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.80 vs. ARLZ: 1.29 )
Ranked among companies with meaningful PB Ratio only.
ARLZ' s PB Ratio Range Over the Past 10 Years
Min: 0.92  Med: 4.99 Max: 24.27
Current: 1.29
0.92
24.27
PS Ratio 1.10
ARLZ's PS Ratio is ranked higher than
79% of the 736 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. ARLZ: 1.10 )
Ranked among companies with meaningful PS Ratio only.
ARLZ' s PS Ratio Range Over the Past 10 Years
Min: 0.78  Med: 5.88 Max: 38.61
Current: 1.1
0.78
38.61
EV-to-EBIT -3.63
ARLZ's EV-to-EBIT is ranked lower than
99.99% of the 559 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. ARLZ: -3.63 )
Ranked among companies with meaningful EV-to-EBIT only.
ARLZ' s EV-to-EBIT Range Over the Past 10 Years
Min: -248.2  Med: -4.6 Max: 154.6
Current: -3.63
-248.2
154.6
EV-to-EBITDA -5.25
ARLZ's EV-to-EBITDA is ranked lower than
99.99% of the 587 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.50 vs. ARLZ: -5.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
ARLZ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -253.3  Med: -5.1 Max: 147.9
Current: -5.25
-253.3
147.9
EV-to-Revenue 3.63
ARLZ's EV-to-Revenue is ranked lower than
57% of the 755 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.22 vs. ARLZ: 3.63 )
Ranked among companies with meaningful EV-to-Revenue only.
ARLZ' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 5.9 Max: 34.1
Current: 3.63
0.1
34.1
Current Ratio 1.11
ARLZ's Current Ratio is ranked lower than
77% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ARLZ: 1.11 )
Ranked among companies with meaningful Current Ratio only.
ARLZ' s Current Ratio Range Over the Past 10 Years
Min: 1.11  Med: 4.93 Max: 43.94
Current: 1.11
1.11
43.94
Quick Ratio 1.04
ARLZ's Quick Ratio is ranked lower than
66% of the 782 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.82 vs. ARLZ: 1.04 )
Ranked among companies with meaningful Quick Ratio only.
ARLZ' s Quick Ratio Range Over the Past 10 Years
Min: 1.04  Med: 4.93 Max: 43.94
Current: 1.04
1.04
43.94
Days Inventory 146.82
ARLZ's Days Inventory is ranked lower than
61% of the 707 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. ARLZ: 146.82 )
Ranked among companies with meaningful Days Inventory only.
ARLZ' s Days Inventory Range Over the Past 10 Years
Min: 70.55  Med: 70.55 Max: 146.82
Current: 146.82
70.55
146.82
Days Sales Outstanding 39.96
ARLZ's Days Sales Outstanding is ranked higher than
75% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. ARLZ: 39.96 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARLZ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.74  Med: 51.99 Max: 137.24
Current: 39.96
4.74
137.24
Days Payable 772.65
ARLZ's Days Payable is ranked higher than
99% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.96 vs. ARLZ: 772.65 )
Ranked among companies with meaningful Days Payable only.
ARLZ' s Days Payable Range Over the Past 10 Years
Min: 274.04  Med: 274.04 Max: 772.65
Current: 772.65
274.04
772.65

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.90
ARLZ's 3-Year Average Share Buyback Ratio is ranked lower than
89% of the 473 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.10 vs. ARLZ: -28.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ARLZ' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -68.9  Med: -1 Max: -0.2
Current: -28.9
-68.9
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.18
ARLZ's Price-to-Median-PS-Value is ranked higher than
97% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. ARLZ: 0.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ARLZ' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.18  Med: 1.31 Max: 45.54
Current: 0.18
0.18
45.54
Earnings Yield (Greenblatt) % -27.68
ARLZ's Earnings Yield (Greenblatt) % is ranked lower than
92% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. ARLZ: -27.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ARLZ' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -47  Med: -3.8 Max: 1372.1
Current: -27.68
-47
1372.1

More Statistics

Revenue (TTM) (Mil) $87.22
EPS (TTM) $ -1.64
Beta0.53
Short Percentage of Float5.96%
52-Week Range $0.95 - 6.70
Shares Outstanding (Mil)66.85

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 119 168 209
EPS ($) -1.19 -0.39 0.07
EPS without NRI ($) -1.19 -0.39 0.07
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ARLZ

Headlines

Articles On GuruFocus.com
Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017 Jul 24 2017 
Aralez Announces National U.S. Commercial Launch Of Zontivity Jun 07 2017 
Aralez to present at the Jefferies Healthcare Conference May 23 2017 
Aralez Announces Voting Results From 2017 Annual And Special Meeting Of Shareholders May 03 2017 
Aralez To Report First Quarter 2017 Financial Results On May 9, 2017 Apr 25 2017 
Aralez Announces Reduction In U.S. Sales Force And Cost Savings Program Apr 05 2017 
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice o Jun 01 2016 
POZEN and Tribute Announce Plan to Proceed With Merger to Form Aralez Pharmaceuticals Dec 07 2015 
Insiders Buy Cheniere Energy, Sell Travelport, Sabre Nov 13 2015 
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of A Oct 15 2014 

More From Other Websites
ETFs with exposure to Aralez Pharmaceuticals, Inc. : September 5, 2017 Sep 05 2017
Aralez Pharmaceuticals, Inc. :ARLZ-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Aug 25 2017
Edited Transcript of ARLZ earnings conference call or presentation 9-Aug-17 1:00pm GMT Aug 15 2017
ARLZ: Looking to Capitalize on Successful Launch of Zontivity® Aug 10 2017
Aralez Reports Second Quarter 2017 Financial Results Aug 09 2017
Aralez To Report Second Quarter 2017 Financial Results On August 9, 2017 Jul 24 2017
ARLZ: Promising Early Data Following Launch of Zontivity®; VIMOVO® Patents Upheld Jul 10 2017
Corporate News Blog - Aralez Announced District Court Decision to Uphold VIMOVO Patents Jun 29 2017
Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents Jun 27 2017
Aralez Announces National U.S. Commercial Launch Of Zontivity Jun 07 2017
Aralez Announces Board Member Resignation Jun 07 2017
Aralez to present at the Jefferies Healthcare Conference May 23 2017
Edited Transcript of ARLZ earnings conference call or presentation 9-May-17 1:00pm GMT May 18 2017
ARLZ: Zontivity to be Officially Launched in June 2017 May 15 2017
Aralez Pharmaceuticals, Inc. :ARLZ-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}